Bristol-Myers Squibb reports positive long-term multiple myeloma data for Empliciti

Bristol-Myers Squibb has announced new clinical trial data showing the effectiveness of its drug Empliciti when used as part of a combination regimen for advanced multiple myeloma.

Four-year follow-up data from the phase III ELOQUENT-2 study has shown that Empliciti plus lenalidomide/dexamethasone can offer prolonged efficacy in patients with relapsed or refractory multiple myeloma, compared with lenalidomide/dexamethasone alone.

The combination therapy demonstrated a sustained reduction in risk of disease progression and death of 29 percent, as well as a 50 percent relative improvement in progression-free survival rates.

These extended follow-up findings represent the longest assessment period for any immuno-oncology agent in relapsed and refractory multiple myeloma, with a safety profile consistent with prior findings also demonstrated.

Dr Jonathan Leith, haematology development lead at Bristol-Myers Squibb, said: "The long-term efficacy data for Empliciti in patients with advanced multiple myeloma shows the combination of this immuno-oncology agent with standard lenalidomide/dexamethasone treatment can improve patient outcomes."

Empliciti is being developed through a collaboration between Bristol-Myers Squibb and AbbVie, with Bristol-Myers Squibb solely responsible for commercial activities.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.